177 related articles for article (PubMed ID: 35842355)
1. Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
Yu W; Du X; Wang W; Lou J; Liu P; Meng L; Jin J
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e867-e873. PubMed ID: 35842355
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
4. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
[TBL] [Abstract][Full Text] [Related]
9. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
Cortes JE; Saglio G; Kantarjian HM; Baccarani M; Mayer J; Boqué C; Shah NP; Chuah C; Casanova L; Bradley-Garelik B; Manos G; Hochhaus A
J Clin Oncol; 2016 Jul; 34(20):2333-40. PubMed ID: 27217448
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
11. Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.
Ahmed R; Singh R; Kapoor J; Chandra Patra P; Agrawal N; Bhurani D; Halder R
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e71-e77. PubMed ID: 36566108
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase].
Chen YL; Wang L; Yan GL; Yang ZZ; Huang ZP; Zhang YS; Zhao Z; Wan CC; Bao Y; Xiang H; Yin H; Chen LF; Xiong YY; Meng L; Li WM
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):98-104. PubMed ID: 30831623
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China.
Chen LF; Yuan GL; Zhong ZD; Zou P; Li DJ; Bao Y; Ren HB; Meng L; Li WM
Curr Med Sci; 2018 Dec; 38(6):1005-1011. PubMed ID: 30536062
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
18. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
Jabbour E; Sasaki K; Haddad FG; Issa GC; Skinner J; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Garcia-Manero G; Takahashi K; Borthakur G; Pemmaraju N; Pierce S; Kantarjian H
Am J Hematol; 2022 Nov; 97(11):1413-1418. PubMed ID: 36054032
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
20. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K; Yamaguchi K; Ito S; Miyagishima T; Shindo M; Wakasa K; Inomata M; Nagashima T; Kondo T; Fujimoto N; Yamamoto S; Yonezumi M; Oyake T; Kowata S; Tsukushi Y; Mine T; Meguro K; Ikeda K; Watanabe R; Saito S; Sato S; Tajima K; Chou T; Kubo K; Oba K; Sakamoto J; Ishida Y;
Eur J Haematol; 2018 Jan; 100(1):27-35. PubMed ID: 28895203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
